Carmignac Gestion’s Teva Pharmaceuticals TEVA Stock Holding History

Carmignac Gestion’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,116,302	Closed	-$352M	–	29
2014 Q4	$352M	Buy	+6,116,302	New	+$341M	3.21%	18

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Carmignac Gestion's TEVA Position: Q1 2015 in Review

Carmignac Gestion sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 6,116,302 shares — an estimated $352M sold.

Carmignac Gestion first reported a position in TEVA in Q4 2014 and held it in 1 quarter. The position peaked at $352M in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Carmignac Gestion reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Carmignac Gestion sold 6,116,302 Teva Pharmaceuticals shares in Q1 2015, an estimated $352M.
Carmignac Gestion first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Carmignac Gestion's Teva Pharmaceuticals position peaked at $352M in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Carmignac Gestion's 13F filing for Q1 2015, filed 11 May 2015.